89Bio, Inc.(ETNB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ETNB 89Bio, Inc.

Market Closed 04-11 16:00:00 EDT

5.53

+0.54

+10.71%

盘后5.80

+0.27+4.88%

18:45 EDT

High5.54	Low4.90	Vol1.83M
Open4.98	D1 Closing5.00	Amplitude12.71%
Mkt Cap807.29M	Tradable Cap594.68M	Total Shares145.98M
T/O9.61M	T/O Rate1.70%	Tradable Shares107.54M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"ETNB","market":"US","secType":"STK","nameCN":"89Bio, Inc.","latestPrice":5.53,"timestamp":1744401600000,"preClose":4.995,"halted":0,"volume":1825386,"hourTrading":{"tag":"盘后","latestPrice":5.8,"preClose":5.53,"latestTime":"18:45 EDT","volume":2322,"amount":13171.475,"timestamp":1744411532396},"delay":0,"floatShares":107537422,"shares":145984182,"eps":-3.505518,"marketStatus":"Market Closed","change":0.535,"latestTime":"04-11 16:00:00 EDT","open":4.98,"high":5.535,"low":4.9,"amount":9611062.525692,"amplitude":0.127127,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-3.505518,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1744617600000},"marketStatusCode":7,"adr":0,"listingDate":1573448400000,"exchange":"NASDAQ","adjPreClose":4.995,"preHourTrading":{"tag":"盘前","latestPrice":5.27,"preClose":4.995,"latestTime":"09:12 EDT","volume":52,"amount":283.9599724,"timestamp":1744377162297},"postHourTrading":{"tag":"盘后","latestPrice":5.8,"preClose":5.53,"latestTime":"18:45 EDT","volume":2322,"amount":13171.475,"timestamp":1744411532396},"volumeRatio":0.5932295294045756,"impliedVol":1.1079,"impliedVolPercentile":0.8606},"requestUrl":"/m/hq/s/ETNB","defaultTab":"news","newsList":[{"id":"2526543593","title":"Vaxcyte Stock Plummets 56% in a Month: Here's the Reason","url":"https://stock-news.laohu8.com/highlight/detail?id=2526543593","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526543593?lang=en_us&edition=full_marsco","pubTime":"2025-04-11 01:07","pubTimestamp":1744304820,"startTime":"0","endTime":"0","summary":"Vaxcyte PCVX is a clinical-stage biotech focused on developing vaccines to prevent or treat bacterial infectious diseases.In the past month, PCVX's shares have nosedived 56%. This downside came after Vaxcyte reported mixed results from a phase II study on its investigational pneumococcal conjugate vaccine  in healthy infants.Adding to this headwind, the broader biotech/drug sector is feeling the pressure from the resignation of a senior FDA official instrumental in driving biotech innovation, which has raised alarms around the agency’s ability to maintain momentum on innovation and regulatory clarity.Vaxcyte’s shares have plummeted more than 62% year to date compared with the industry’s 8% decline, as seen in the chart below. During this timeframe, the stock has also underperformed the broader Medical sector and the S&P 500 Index. The company’s shares are also trading below its 50 and 200-day moving averages.Vaxcyte intends to report full post-dose 4 booster data for VAX-24 by the end ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vaxcyte-stock-plummets-56-month-170700030.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1894683348.USD","SG9999002232.USD","LU0058720904.USD","SG9999001176.SGD","IE0002270589.USD","LU0868494617.USD","IE00B19Z3581.USD","LU0289739699.SGD","IE00B19Z3B42.SGD","BK4550","BK4588","LU0170899867.USD","LU0566484027.USD","BK4007","LU1066053197.SGD","PCVX","LU0225284248.USD","LU1023059063.AUD","LU1057294990.SGD","LU1559883803.SGD","IE000M9KFDE8.USD","BK4585","BK4581","ETNB","BK4534","SG9999013999.USD","LU0234572021.USD","BK4599","LU0456855351.SGD","BK4139","IE0009354923.USD","LU0985481810.HKD","BK4592","IE00BLSP4452.SGD","ANIP","LU0225771236.USD","BK4533","LU0122379950.USD","LU1066051498.USD","LU0306806265.USD","PFE","SG9999011175.SGD","BK4568","IE00BLSP4239.USD","LU0321505868.SGD","LU0306807586.USD","LU0053671581.USD","SGXZ57979304.SGD","LU1883839398.USD"],"gpt_icon":1},{"id":"2525437894","title":"VRTX Secures Nod for Expanded Use of CF Drug Kaftrio in Europe","url":"https://stock-news.laohu8.com/highlight/detail?id=2525437894","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525437894?lang=en_us&edition=full_marsco","pubTime":"2025-04-08 18:55","pubTimestamp":1744109700,"startTime":"0","endTime":"0","summary":"Vertex Pharmaceuticals VRTX announced that the European Commission  has expanded the label of its blockbuster cystic fibrosis  drug, Kaftrio, to treat all patients aged two years and older who have at least one non-class I mutation in the CFTR gene.This approval was expected as the EMA’s Committee for Medicinal Products for Human Use  issued a positive opinion recommending Kaftrio’s approval in February for the above indication. With this expanded label, nearly 4,000 more CF patients living in the region are now eligible for treatment with the drug.Kaftrio is already approved for use in CF patients aged two years and older who have at least one F508del mutation in the CFTR gene.The drug is marketed by Vertex for similar indications in the United States under the trade name Trikafta.Year to date, shares of Vertex have gained 18% against the industry’s 7% decline.Estimates for 89bio’s loss per share have narrowed from $2.51 to $1.98 for 2025 in the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vrtx-secures-nod-expanded-cf-105500149.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BFTCPJ56.SGD","BK4588","IE0002141913.USD","BK4568","SGXZ57979304.SGD","VERX","LU1430594728.SGD","SG9999001176.USD","ETNB","BK4201","IE0002270589.USD","LU1559883803.SGD","LU1035775433.USD","LU0823416689.USD","LU2362540622.SGD","LU1585245621.USD","IE00B894F039.SGD","SG9999013999.USD","BK4551","BK4093","BK4023","LU0320765992.SGD","BK4139","ANIP","LU2456880835.USD","BK4533","LU2462157665.USD","VRTX","BK4567","IE00B19Z3B42.SGD","IE00BJJMRZ35.SGD","LU1093756168.USD","LU0417517546.SGD","LU2417539215.USD","IE00BZ9MQY76.HKD","CF","LU2236285917.USD","IE00B19Z9P08.USD","SG9999001176.SGD","LU0289739699.SGD","BK4007","LU2237438978.USD","EC","LU0109394709.USD","LU2362541273.HKD","IE00BJT1NW94.SGD","LU0757428866.USD","LU2324357040.USD"],"gpt_icon":1},{"id":"2525318890","title":"FDA Grants Three Fast Track Tags to Allogene's Autoimmune Disease Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2525318890","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525318890?lang=en_us&edition=full_marsco","pubTime":"2025-04-08 18:46","pubTimestamp":1744109160,"startTime":"0","endTime":"0","summary":"Allogene Therapeutics ALLO announced that the FDA has granted three fast track designations to its investigational CRISPR-based allogeneic CAR-T therapy, ALLO-329.These designations apply to three autoimmune diseases — systemic lupus erythematosus , idiopathic inflammatory myopathy  and diffuse systemic sclerosis .How Does the Fast Track Tag Benefit ALLO’s Drug Development?Fast track designation is designed to facilitate the development and expedite the review of drugs that treat serious conditions, meet an unmet medical need, or offer a potential advantage over existing treatments. Per the FDA, the purpose of granting this designation is to ‘get important new drugs to the patient earlier.’。In the past 60 days, estimates for CytomX Therapeutics’ 2025 EPS have improved from a loss of 31 cents to a profit of 25 cents. During the same timeframe, estimates for loss per share for 2026 have","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-grants-three-fast-track-104600523.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B5TLWC47.USD","BK4505","BK4585","SLE","BK4567","CTMX","BK4007","BK4588","ETNB","BK4077","ANIP","ALLO","BK4139","IE00BFXG0V08.USD","IIM","IE00BYQQ9H92.USD","FAST","BK4104"],"gpt_icon":0},{"id":"2524260088","title":"BMRN's PKU Drug Palynziq Meets Goal in Late-Stage Pediatric Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2524260088","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524260088?lang=en_us&edition=full_marsco","pubTime":"2025-04-03 22:14","pubTimestamp":1743689640,"startTime":"0","endTime":"0","summary":"BioMarin BMRN has announced positive results from the phase III PEGASUS study evaluating Palynziq  in adolescents aged 12-17 years with phenylketonuria .The study achieved its primary endpoint – patients treated with Palynziq achieved a statistically significant lowering in blood phenylalanine  levels compared to diet alone. The safety results were also consistent with the known profile of the drug.Palynziq is already approved in the United States to reduce blood Phe concentration in adults aged 18 years and older with PKU. The drug is currently the only enzyme therapy to treat the disease in this age group.PKU is a rare genetic disorder that prevents the body from breaking down Phe, an amino acid found in protein-rich foods, leading to toxic levels that can cause severe neurological damage. While newborn screening enables early diagnosis, lifelong dietary management is challenging, creating demand for innovative treatments like those developed by BioMarin.In the past 60 days, estimate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bmrns-pku-drug-palynziq-meets-141400981.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BMRN","IE00B19Z3B42.SGD","BK4566","ETNB","IE0002270589.USD","BK4139","IE00B7SZLL34.SGD","SSI","BK4585","ANIP","CTMX","IE00B19Z3581.USD"],"gpt_icon":0},{"id":"2524460415","title":"LXRX Stock Moves Up 30% in a Week: What is Driving This Rally?","url":"https://stock-news.laohu8.com/highlight/detail?id=2524460415","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524460415?lang=en_us&edition=full_marsco","pubTime":"2025-04-02 22:18","pubTimestamp":1743603480,"startTime":"0","endTime":"0","summary":"Shares of Lexicon Pharmaceuticals LXRX have jumped 30% after signing a licensing deal for its pre-clinical obesity drug LX9851 with pharma giant Novo Nordisk NVO last week.Per the deal terms, Lexicon will complete certain preclinical activities before Novo Nordisk takes over the development, manufacturing and commercialization of LX9851. NVO will also be responsible for LX9851’s investigational new drug  filing.In return, LXRX is eligible to receive $75 million as an upfront payment from NVO. Including milestone payments, the deal is worth up to $1 billion. Lexicon will also earn tiered royalties on potential net sales of the drug.Post the above setback, LXRX decided to discontinue developing the drug for the T1D indication and announced plans to reduce its workforce by 60%.A couple of better-ranked stocks from the sector are ANI Pharmaceuticals ANIP and 89bio ETNB. ANIP sports a Zacks Rank #1  at present and ETNB carries a Zacks Rank #2","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lxrx-stock-moves-30-week-141800883.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","ANIP","BK4599","ETNB","NVO","LU1093756168.USD","LXRX","BK4588","LU1093756325.SGD","BK4139","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","BK4007","BK4532","LU0154236417.USD"],"gpt_icon":1},{"id":"2523685649","title":"FDA Accepts Merck's Filing for Subcutaneous Version of Keytruda","url":"https://stock-news.laohu8.com/highlight/detail?id=2523685649","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523685649?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 23:20","pubTimestamp":1743175200,"startTime":"0","endTime":"0","summary":"Merck MRK announced that the FDA has accepted its regulatory filing seeking approval for the subcutaneous  formulation of the blockbuster drug Keytruda .This filing seeks the agency’s nod for the SC version across all solid tumor indications for which the drug’s intravenous  version is already approved.A final decision is expected by Sept. 23, 2025.The regulatory filing is supported by data from the pivotal phase III 3475A-D77 study that evaluated Keytruda SC against the IV version  for the first-line treatment of adult patients with metastatic non-small cell lung cancer. As announced by Merck in November, the study achieved its primary endpoints, showing that the treatment with the SC version of the drug was at least as effective as the IV version.An approval of the SC version also benefits both patients and physicians. Delivering a drug SC instead of IV can significantly reduce administrat","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-accepts-mercks-filing-subcutaneous-152000184.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","LU1023059063.AUD","LU1093756325.SGD","LU1037948897.HKD","IE00BSNM7G36.USD","IE00BN8TJ469.HKD","BK4139","IE00BLSP4239.USD","LU1066051811.HKD","SG9999002224.SGD","IE00BJJMRZ35.SGD","LU0058720904.USD","LU0985320562.USD","SG9999015341.SGD","LU0208291251.USD","LU1585245621.USD","SG9999014575.USD","LU0070302665.USD","ETNB","LU0965509283.SGD","LU1037948541.HKD","LU1066053197.SGD","SG9999001176.SGD","SG9999015358.SGD","LU1941712264.USD","LU1989772923.USD","MRK","LU0266013472.USD","LU0289739699.SGD","LU0320765489.SGD","LU0320765646.SGD","LU1934455863.HKD","IE00BJT1NW94.SGD","ANIP","LU1989772840.SGD","LU0861579265.USD","LU1066051498.USD","IE000M9KFDE8.USD","IE00B4R5TH58.HKD","LU1983299246.USD","IE0002141913.USD","CTMX","LU0965509010.AUD","LU2023250843.SGD","BK4516","BK4550","LU2112291526.USD","LU1116320737.USD","LU2361044865.SGD"],"gpt_icon":0},{"id":"2522079582","title":"FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib","url":"https://stock-news.laohu8.com/highlight/detail?id=2522079582","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522079582?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 19:56","pubTimestamp":1742903760,"startTime":"0","endTime":"0","summary":"Sanofi SNY announced that the FDA has accepted its regulatory filing seeking approval for its investigational BTK inhibitor tolebrutinib to treat non-relapsing secondary progressive multiple sclerosis  and slow disability accumulation independent of relapse activity in adults.The filing has been granted priority review by the FDA, bringing down the review period by four months. A final decision is expected by Sept. 28, 2025.The FDA filing is supported by data from three late-stage studies — one  in nrSPMS and two  in relapsing MS . Data from these studies showed that patients treated with tolebrutinib delayed the time to onset of six-month confirmed disability progression when compared to placebo. A similar regulatory filing for the drug is currently under review by the EMA, which is also supported by data from these studies.Per Sanofi, the above results make tolebrutinib the first and the only brain-penetrant BTK inhibitor to treat both the above MS indications. If approved, tolebruti","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-accepts-sanofis-filing-multiple-115600487.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1074936037.SGD","BK4516","LU0320765646.SGD","IE00BFXG1179.USD","MG","LU1363072403.SGD","LU2111349929.HKD","ANIP","LU1720051108.HKD","LU1720051017.SGD","ETNB","BK4585","BK4534","BK4139","LU2271345857.HKD","LU0314104364.USD","IE00BZ1G4Q59.USD","BK4581","LU0795875169.SGD","IE0031619046.USD","LU0267386448.USD","LU0225283273.USD","LU1732800096.USD","LU2028103732.USD","SNY","IE00BKVL7J92.USD","IE00B19Z4B17.USD","LU1989772840.SGD","BK4504","BK4123","CTMX","LU1668664300.SGD","LU0912757837.SGD","LU2133065610.SGD","LU0098860793.USD","LU1548497426.USD","LU1732799900.SGD","LU0158827948.USD","LU0971096721.USD","LU1162221912.USD","LU2089283258.USD","SNYNF","LU0106261372.USD","LU2023251221.USD","LU0158827781.USD","LU0106831901.USD","LU2357305700.SGD","IE00B66KJ199.SGD","BK4588"],"gpt_icon":0},{"id":"2521940256","title":"Elevation Oncology Plunges 42% on Ending Development of Lead Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2521940256","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521940256?lang=en_us&edition=full_marsco","pubTime":"2025-03-22 01:03","pubTimestamp":1742576580,"startTime":"0","endTime":"0","summary":"Shares of Elevation Oncology ELEV plunged more than 40% yesterday after reporting disappointing data from a phase I study on its lead pipeline drug EO-3021 for treating advanced, unresectable or metastatic gastric and gastroesophageal junction  cancers.Data from the study showed that patients who were treated with ELEV’s lead drug showed an objective response rate  of 22.2% —out of 36 evaluable patients, there was one complete response and seven partial responses.Following the disappointing study results, Elevation Oncology decided not to pursue further clinical development of EO-3021. Instead, the company will now shift its focus to solid tumor candidate EO-1022, for which an investigational new drug  filing with the FDA is expected next year. As a result of this decision, ELEV is now without a pipeline candidate in clinical development. These factors were likely responsible for the significant drop in share price.In the past 60 days, estimates for CytomX Therapeutics’ 2025 EPS have i","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/elevation-oncology-plunges-42-ending-170300990.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ANIP","BK4539","ELEV","ETNB","ORR","CTMX","BK4585","BK4139","BK4007"],"gpt_icon":0},{"id":"2521946256","title":"Akebia Stock Drops 28% on Pricing of $50M Common Stock Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2521946256","media":"Zacks","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521946256?lang=en_us&edition=full_marsco","pubTime":"2025-03-22 01:01","pubTimestamp":1742576460,"startTime":"0","endTime":"0","summary":"Akebia Therapeutics AKBA recently announced that it is floating a secondary issue of 25 million shares of its common stock to the public at an issue price of $2 per share, amounting to $50 million.The company also granted an option to underwriters of the issue to purchase an additional 3.75 million shares at the same price.The secondary offering is expected to close today.Akebia’s shares fell more than 28% yesterday after the announcement. Though the issue does not significantly dilute the existing shareholder base, the issue price per share did not sit well with investors. The issue price was at a discount to the closing price on Thursday, with the stock closing at $2.04.Year to date, shares of Akebia have outperformed the industry.Akebia plans to use the net proceeds from this new issue and its existing cash balance to fund working capital and general corporate purposes, which may include supporting research, development and commercial activities for its marketed and pipeline drugs.A","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/akebia-stock-drops-28-pricing-170100693.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CTMX","ANIP","AKBA","BK4585","ETNB","BK4007","BK4139"],"gpt_icon":0},{"id":"2520243757","title":"Analysts Offer Insights on Healthcare Companies: 89bio (ETNB), Gain Therapeutics (GANX) and Boston Scientific (BSX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2520243757","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520243757?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 18:50","pubTimestamp":1742467809,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on 89bio (ETNB – Research Report), Gain Therapeutics (GANX – Researc...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-89bio-etnb-gain-therapeutics-ganx-and-boston-scientific-bsx?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-89bio-etnb-gain-therapeutics-ganx-and-boston-scientific-bsx?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ETNB","LU1791710400.SGD","LU2242649171.HKD","LU0345769631.USD","IE00BFTCPJ56.SGD","LU2491050071.SGD","LU0187121727.USD","LU0048584097.USD","BK4585","LU1989772923.USD","LU2362541273.HKD","LU1983299246.USD","LU2362541513.USD","BK4137","BK4581","HCSG","IE00B2B36J28.USD","LU0353189763.USD","BK4139","BK4588","LU0353189680.USD","LU2506952170.USD","LU0011850046.USD","LU1291159041.SGD","LU1989764664.SGD","LU0251132253.USD","LU1804176565.USD","LU0267386448.USD","LU0950375773.USD","GANX","LU1791710582.SGD","IE0009355771.USD","LU2265009873.SGD","IE00BJT1NW94.SGD","LU2087625088.SGD","LU1718418525.SGD","LU0882574055.USD","LU0077335932.USD","LU2324357040.USD","LU2506952097.USD","LU0238689110.USD","LU0528227936.USD","LU1023059063.AUD","BSX","LU2491050154.USD","LU0345769128.USD","LU1153585028.USD","LU0266013472.USD","LU2491049909.HKD","BK4082"],"gpt_icon":0},{"id":"2519187770","title":"Goldman Sachs Initiates Coverage on 89bio With Neutral Rating, $11 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2519187770","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519187770?lang=en_us&edition=full_marsco","pubTime":"2025-03-14 19:20","pubTimestamp":1741951241,"startTime":"0","endTime":"0","summary":"89bio (ETNB) has an average rating of Buy and mean price target of $27.55, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and res","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ETNB"],"gpt_icon":0},{"id":"2519745428","title":"89bio Initiated at Neutral by Goldman Sachs","url":"https://stock-news.laohu8.com/highlight/detail?id=2519745428","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519745428?lang=en_us&edition=full_marsco","pubTime":"2025-03-14 18:45","pubTimestamp":1741949100,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ETNB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 14, 2025 06:45 ET (10:45 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ETNB"],"gpt_icon":0},{"id":"2519856750","title":"BUZZ-U.S. STOCKS ON THE MOVE-Metropolitan Bank, Fossil, MeiraGTx","url":"https://stock-news.laohu8.com/highlight/detail?id=2519856750","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519856750?lang=en_us&edition=full_marsco","pubTime":"2025-03-13 23:47","pubTimestamp":1741880850,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Metropolitan Bank, Fossil, MeiraGTxEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250313:nL4N3PW19Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2250418816.HKD","IE00BJJMRX11.SGD","MCB","BK4570","AEO","NEM","KNSA","LU2430703178.SGD","PCAR","BBW","FOSL","NOVA","AEYE","DLTR","ATEN","LU0162691827.USD","IE00BMPRXQ63.HKD","SPIR","LU0238689110.USD","MGTX","LU2065169927.USD","LU1496350171.SGD","LU2498475776.HKD","ETNB","GIII","LU1043141123.HKD","LU2317271919.USD","NN","TARS","LYV","AVAH","NVAX","TRIB","APGE","KYMR","ALKT","LU2506952170.USD","MNTK","LU0276348264.USD","LU0096364046.USD"],"gpt_icon":1},{"id":"2519856110","title":"Citi says SMid biotechs alternative to large caps as it starts coverage","url":"https://stock-news.laohu8.com/highlight/detail?id=2519856110","media":"Investing.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519856110?lang=en_us&edition=full_marsco","pubTime":"2025-03-13 23:34","pubTimestamp":1741880086,"startTime":"0","endTime":"0","summary":"Investing.com --Citi has expanded its biopharmaceutical research coverage, initiating coverage on seven small- and mid-cap  biotechnology companies. Citi said SMid biotechs remain an attractive alternative to large-cap pharmaceutical firms, particularly amid healthcare policy uncertainties. Citi initiated coverage with Buy ratings on 89bio , price target $25. Apogee , price target $95. Avidity, price target $70, BioNTech , price target $145. Kiniksa, price target $40. Kymera, price target $52. Brokerage maintains a Sell rating on PTC Therapeutics  while raising its price target to $50 from $46.Despite near-term volatility, Citi favors a “barbell” strategy, balancing exposure between high-growth large caps like Eli Lilly  and Vertex Pharmaceuticals  with catalyst-driven SMid biotechs.Among the newly covered stocks, Citi named Apogee, Avidity, and Kymera as its preferred SMid biotechs, citing their focus on unmet medical needs and differentiated research platforms.Citi said SMid biotech ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/citi-says-smid-biotechs-alternative-153446544.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2361044865.SGD","NQmain","APOG","USJW.SI","NVIW.SI","LU2468319806.SGD","LU1127390331.HKD","IE0009355771.USD","MNQmain","LU1868836914.USD","MRNA","LU2023250504.SGD","LU0466842654.USD","IE0002270589.USD","BK4548",".IXIC","LU1093756168.USD","TSYW.SI","LU0198837287.USD","BK4533","LU0203201768.USD","BNTX","SG9999015952.SGD","LU1093756325.SGD","ETNB","LU0689472784.USD","LU1804176565.USD","LU2237443382.USD","SG9999015978.USD","LU1551013425.SGD","QLD","LU1430594728.SGD","LU0256863902.USD","LU0289739699.SGD","LU1868836591.USD","USAW.SI","LU2237443465.HKD","SGXZ81514606.USD","LU0097036916.USD","LU0823416689.USD","PSQ","QID","SQQQ","VRTX","PTCT","TQQQ","LU0820561818.USD","LU0096364046.USD"],"gpt_icon":1},{"id":"2519183238","title":"89Bio Shares up 2% After Citigroup Initiates Coverage With 'Buy' Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2519183238","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519183238?lang=en_us&edition=full_marsco","pubTime":"2025-03-13 21:34","pubTimestamp":1741872891,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250313:nFWN3PW1BR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ETNB","BK4139","BK4585"],"gpt_icon":0},{"id":"2519836091","title":"89Bio Shares up 3.6% Premarket After Citigroup Initiates Coverage With 'Buy' Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2519836091","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519836091?lang=en_us&edition=full_marsco","pubTime":"2025-03-13 20:39","pubTimestamp":1741869588,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250313:nL4N3PW0ZO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","ETNB","BK4139"],"gpt_icon":0},{"id":"2519683669","title":"BUZZ-Citi initiates coverage on 89bio with 'buy' rating on potential for MASH therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2519683669","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519683669?lang=en_us&edition=full_marsco","pubTime":"2025-03-13 20:24","pubTimestamp":1741868643,"startTime":"0","endTime":"0","summary":"BUZZ-Citi initiates coverage on 89bio with 'buy' rating on potential for MASH therapy** Brokerage Citi initiates coverage on 89bio ETNB.O with \"buy\" rating** Brokerage sets PT at $25, representing a near triple upside to the stock's last close** Citi remains optimistic about co's experimental drug, pegozafermin, for patients with a type of fatty liver disease known as metabolic dysfunction-associated steatohepatitis ** \"If 89bio can replicate its early results of pegozafermin in larger trials and show a synergistic effect when used in combination of GLP-1s, pegozafermin could become a significant player in the MASH space\", says Citi** Eight of 9 brokerages rate the stock \"buy\" or higher, 1 \"hold\"; their median PT is $29.67, according to data compiled by LSEG** Up to last close, ETNB has fallen 35.1% in the past 12 months  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250313:nL4N3PW0V4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ETNB"],"gpt_icon":0},{"id":"2519308880","title":"Citigroup Initiates 89bio Inc at Buy With $25 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2519308880","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519308880?lang=en_us&edition=full_marsco","pubTime":"2025-03-13 19:12","pubTimestamp":1741864369,"startTime":"0","endTime":"0","summary":"89bio Inc (ETNB) has an average rating of buy and mean price target of $29.67, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ETNB"],"gpt_icon":0},{"id":"2519878538","title":"BUZZ-Citi starts coverage on 'insulated' SMid biotechs amid healthcare policy uncertainty","url":"https://stock-news.laohu8.com/highlight/detail?id=2519878538","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519878538?lang=en_us&edition=full_marsco","pubTime":"2025-03-13 18:56","pubTimestamp":1741863404,"startTime":"0","endTime":"0","summary":"BUZZ-Citi starts coverage on 'insulated' SMid biotechs amid healthcare policy uncertainty   ** Brokerage Citi initiates coverage on eight small and mid-cap  biotechs - 89bio ETNB.O, Apogee Therapeutics APGE.O, Avidity Biosciences RNA.O, BioNTech 22UAy.DE, Kiniksa Pharmaceuticals KNSA.O, Kymera Therapeutics KYMR.O, Moderna MRNA.O and PTC Therapeutics PTCT.O** Citi suggests SMid biotechs could be a good alternative to larger-cap stocks amid healthcare policy uncertainty** Recent economic uncertainties, including increased tariffs and slowing economic growth, have \"underscored the defensive attributes\" of biotech and pharma stocks, brokerage says ** Higher-growth large caps such as Eli Lilly LLY.N and Vertex Pharma VRTX.O are likely able to absorb potential policy headwinds and \"catalyst-driven\" SMid biotechs are \"insulated from macro uncertainties\" - Citi** YTD, S&P500 Health Care index .SPXHC has grown ~5%, NYSE Arca Pharmaceutical Index .DRG has gained ~6% and NASDAQ Biotechnology Inde","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250313:nL4N3PW0SW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2211815571.USD","LU1917777945.USD","VRTX","LU2063271972.USD","BK4533","LU1064131342.USD","LU1868836591.USD","LU0096364046.USD","LU2237443978.SGD","LU1868837300.USD","LU0006306889.USD","IE0002141913.USD","KNSA","ETNB","IE00B894F039.SGD","LU2089984988.USD","LU1291159041.SGD","IE00BFTCPJ56.SGD","LU2237443465.HKD","LU2265009873.SGD","LU1868837136.USD","SG9999014898.SGD","LU0238689110.USD","LU0417517546.SGD","BK4139","LU0097036916.USD","LU1280957306.USD","LU0109391861.USD","MRNA","BK4007","SGXZ81514606.USD","LU1720051017.SGD","LU0320765059.SGD","PTCT","IE00B19Z3B42.SGD","SG9999018865.SGD","LU1093756325.SGD","RNA","LU0820561909.HKD","SG9999017495.SGD","LU0061475181.USD","LU2362541513.USD","IE00BJLML261.HKD","LU0106261372.USD","KYMR","APGE","LU1551013342.USD","LU2023250504.SGD","LU1989771016.USD"],"gpt_icon":1},{"id":"2517316735","title":"Is 89BIO (ETNB) Stock Outpacing Its Medical Peers This Year?","url":"https://stock-news.laohu8.com/highlight/detail?id=2517316735","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517316735?lang=en_us&edition=full_marsco","pubTime":"2025-03-06 22:40","pubTimestamp":1741272007,"startTime":"0","endTime":"0","summary":"The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has 89BIO  been one of those stocks this year?By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.89BIO is one of 1012 companies in the Medical group. The Medical group currently sits at #3 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. 89BIO is currently sporting a Zacks Rank of #2 .Eton Pharmaceuticals, Inc.  is another Medical stock that has outperformed the sector so far this year. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/89bio-etnb-stock-outpacing-medical-144007849.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ETNB","BK4585","ETON","BK4007","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.89bio.com","stockEarnings":[{"period":"1week","weight":-0.0416},{"period":"1month","weight":-0.3377},{"period":"3month","weight":-0.1505},{"period":"6month","weight":-0.2901},{"period":"1year","weight":-0.4546},{"period":"ytd","weight":-0.2928}],"compareEarnings":[{"period":"1week","weight":0.0567},{"period":"1month","weight":-0.0446},{"period":"3month","weight":-0.0802},{"period":"6month","weight":-0.0787},{"period":"1year","weight":0.0308},{"period":"ytd","weight":-0.089}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.111427},{"month":2,"riseRate":0.666667,"avgChangeRate":0.102838},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.098837},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.140348},{"month":5,"riseRate":0.6,"avgChangeRate":0.054165},{"month":6,"riseRate":0.6,"avgChangeRate":-0.022743},{"month":7,"riseRate":0.6,"avgChangeRate":0.088741},{"month":8,"riseRate":1,"avgChangeRate":0.16496},{"month":9,"riseRate":0.4,"avgChangeRate":-0.059438},{"month":10,"riseRate":0.4,"avgChangeRate":-0.003798},{"month":11,"riseRate":0.6,"avgChangeRate":-0.000698},{"month":12,"riseRate":0.333333,"avgChangeRate":0.097135}],"exchange":"NASDAQ","name":"89Bio, Inc.","nameEN":"89Bio, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.4","shortVersion":"4.32.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"89Bio, Inc.(ETNB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest 89Bio, Inc.(ETNB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"89Bio, Inc.,ETNB,89Bio, Inc.股票,89Bio, Inc.股票老虎,89Bio, Inc.股票老虎国际,89Bio, Inc.行情,89Bio, Inc.股票行情,89Bio, Inc.股价,89Bio, Inc.股市,89Bio, Inc.股票价格,89Bio, Inc.股票交易,89Bio, Inc.股票购买,89Bio, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"89Bio, Inc.(ETNB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest 89Bio, Inc.(ETNB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction